AbbVie expands siRNA push with $335m ADARx deal
This marks AbbVie’s second major siRNA deal following its $1.4bn acquisition of Aliada Therapeutics last year.
Therapy Area
Boehringer partners Tempus AI to enhance cancer therapy pipeline
Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies
GSK to spend $2bn on Phase III liver disease drug acquisition
Eligo Bioscience secures grant to advance topical gene delivery platform
GSK and iTeos drop anti-TIGIT drug following trial failure
GLP-1RAs show anti-cancer benefits beyond weight loss
MHRA approves AstraZeneca’s Trixeo Aerosphere inhaler for COPD
